White House officials dismiss criticism that President Biden’s comments on booster shots amount to undue pressure on public health experts.
Scientific advisers to the C.D.C. endorsed additional doses of the Pfizer-BioNTech vaccine for older Americans but not for health care workers, in a possible rift with regulators.
Immunizations will quickly begin nationwide, officials predicted.
U.S. experts weigh the risks for younger women and cases of a rare blood-clotting disorder, and lift the pause in giving the one-shot vaccine.
An advisory committee debated the very few cases of a rare blood disorder and worried about the suspension’s effect on global needs for a one-shot, easy-to-ship vaccine.
The recommendation was a compromise aimed at getting the coronavirus vaccine to the most vulnerable of two high-risk groups.
The vaccine debate is the latest example of how our coronavirus choices are inescapably political.
After a brush with the U.S. Department of Health and Human Services, professional Santa Clauses are just trying to get through this holiday season safely.
The C.D.C. director will decide by Wednesday whether to accept the recommendation. States aren’t required to follow it, but most are expected to.
A C.D.C. advisory panel will decide on its recommendations on Tuesday afternoon. Here’s what we expect, along with answers to other questions about the new shot.
Federal officials have suggested that corrections staff receive high priority for a coronavirus vaccine, but not the millions of vulnerable inmates held in U.S. facilities.
A committee that advises the C.D.C.’s director is working on a plan to equitably distribute immunizations when they become available.
Despite the president’s repeated claims that a vaccine will be available in October, scientists, companies and federal officials all say that most people won’t get one until well into next year.
The agency told public health agencies that two unidentified vaccines might be ready by October or November. We explain how vaccine trials work, when one might be ready, and who may get them first.
When a coronavirus vaccine hits the market, it will be a key tool in putting an end to the pandemic. A federal committee is debating who in the population should get it first.